Quest Diagnostics (DGX) Tops Q3 EPS by 2c; Narrows FY16 Outlook

Quest Diagnostics (NYSE: DGX) reported Q3 EPS of $1.37, $0.02 better than the analyst estimate of $1.35. Revenue for the quarter came in at $1.89 billion versus the consensus estimate of $1.89 billion.

GUIDANCE:

Quest Diagnostics sees FY2016 EPS of $5.07-$5.12, versus prior guidance of $5.02-$5.17 and the consensus of $5.11. Quest Diagnostics sees FY2016 revenue of $7.51 billion, versus prior guidance of $7.47-7.54 billion and the consensus of $7.52 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• AbbVie updates 2026 EPS guidance after $291M IPR&D charge
• Morgan Stanley Resumes Bath & Body Works Inc. (BBWI) at Equalweight